Most of us have never heard of it, but nonalcoholic steatohepatitis is a chronic disease that threatens the lives of around 30 million people in the U.S. alone. There aren't any available treatments for NASH, and it looks like Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) could generate billions for its shareholders with a drug that's several steps ahead of the competition.Does Intercept's lead over a tsunami of competitors make the stock a buy now?
Similar Stories to Is Intercept Pharmaceuticals, Inc. A Buy? on Bing News
newsfeedback@fool.com (Cory Renauer), The Motley Fool
Fri, 08/17/2018 - 6:54am
BING NEWS:
- Regeneron's blockbuster eye drug posts weaker sales due to inventory impact
U.S. drugmaker Regeneron Pharmaceuticals Inc missed Wall Street estimates for first-quarter profit on Thursday due to softer sales of its blockbuster eye drug Eylea and its eczema treatment, Dupixent.
05/2/2024 - 7:02 am | View Link - Rocket Pharmaceuticals Upgraded to Buy: Here's Why
Investors might want to bet on Rocket Pharmaceuticals (NASDAQ: RCKT), as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful ...
04/30/2024 - 10:46 am | View Link - DEA seeks to reclassify marijuana, allow prescriptions for first time: Reports
The federal government's plan would recategorize pot, once deemed highly dangerous, addictive and without medical use, as a prescribable medication.
04/30/2024 - 6:51 am | View Link - Analysts Offer Insights on Healthcare Companies: Edwards Lifesciences (EW), BioMarin Pharmaceutical (BMRN) and Hookipa Pharma (HOOK)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Edwards Lifesciences (EW – Research Report), BioMarin ...
04/29/2024 - 7:12 pm | View Link - US FDA approves X4 Pharmaceuticals' therapy for immunodeficiency disease
X4 Pharmaceuticals said on Monday the U.S. FDA has approved its therapy to treat a rare genetic immunodeficiency disease in patients 12 years of age and older.
04/29/2024 - 12:59 am | View Link - More
- Intercept Pharmaceuticals | LinkedIn
28. Intercept Pharmaceuticals | 62,002 followers on LinkedIn. Our mission is to build a healthier tomorrow for patients with rare and serious liver diseases. | We are a biopharmaceutical company ...
05/4/2024 - 2:05 am | View Website - Intercept Receives Complete Response Letter from FDA for
Intercept Receives Complete Response Letter from FDA for Obeticholic Acid as a Treatment for Pre-Cirrhotic Fibrosis due to NASH June 22, 2023 17:45 ET | Source: Intercept Pharmaceuticals, Inc.
05/3/2024 - 9:04 pm | View Website - FDA Accepts Intercept’s New Drug Application for OCA for the Treatment ...
Updated Thu, Jan 19, 2023 4 min read. Intercept Pharmaceuticals, Inc. NDA is supported by robust NASH clinical development program, including two positive interim analyses from the Phase 3 ...
05/2/2024 - 10:17 pm | View Website - Intercept Announces FDA Acceptance of Supplemental New Drug Application ...
Intercept Announces FDA Acceptance of Supplemental New Drug Application for Ocaliva® (obeticholic acid) for the Treatment of PBC. Intercept Pharmaceuticals, Inc. Thu, Feb 29, 2024, 8:30 AM 8 min ...
05/2/2024 - 7:03 pm | View Website - Homepage
Innovating to solve some of today’s toughest medical challenges. Using key discoveries in the field of liver health, we’re advancing treatments for rare and serious liver diseases. Our portfolio is based on novel scientific targets with the potential for therapeutic application across multiple liver diseases.
05/2/2024 - 11:25 am | View Website - More
Welcome to Wopular
Wopular is an
online newspaper rack,
giving you a summary view of the top headlines from the top news sites.
Senh Duong (Founder)
Wopular,
MWB,
RottenTomatoes
MoviesWithButter : Our Sister Site
- "Expendables 4" Starts Shooting This Fall, Says Randy Couture at the Arnold Sports Festival more
- “Expendables 4” Gets Funding Interest from “Ip Man 3” Financier more
- "Ip Man 3" Distributor Suspected of Box Office Fraud, Parent Company Loses $200M in Market Cap more
- Yen Targets "Ip Man 4" for 2018 Release; Discusses Film with Director, Producer more
- "Ip Man 3" Shatters Expectations with $72M Opening [China Box Office] more